Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 242Lymphoma 237Lymphoma, Non-Hodgkin 206Leukemia, Lymphocytic, Chronic, B-Cell 186Lymphoma, Large B-Cell, Diffuse 179Lymphoma, Follicular 175Lymphoma, B-Cell 113Lymphoma, Mantle-Cell 107Hodgkin Disease 105Leukemia, Myeloid, Acute 102Recurrence 98Multiple Myeloma 92Burkitt Lymphoma 90Leukemia 78Neoplasms 68Lymphoma, B-Cell, Marginal Zone 60Hematologic Neoplasms 59Myelodysplastic Syndromes 56Waldenstrom Macroglobulinemia 48Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 43Lymphoma, T-Cell 43Lymphoma, T-Cell, Peripheral 36Lymphoma, T-Cell, Cutaneous 31Leukemia, Biphenotypic, Acute 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Leukemia, B-Cell 27Mycosis Fungoides 25Lymphoma, Large-Cell, Anaplastic 25Sarcoma 24Breast Neoplasms 22

Interventions

gamma-Globulins 1Saline Solution 1Panzyga 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Agammaglobulinemia × Lymphoid × 90 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645107 2026-04-13

EXCELL

Grifols Therapeutics LLC

Phase 3 Recruiting
386 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Bacterial Infections, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡